Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss

 
• By Alaric DeArment
  
Travere announced data from the Phase III PROTECT study of Filspari in IgA nephropathy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D